A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This trial will be a two steps Phase I clinical study in patients with advanced solid tumors
with an escalating phase (Step 1) followed by an expansion phase (Step 2) of BI 765063, a
monoclonal antibody (mAb) antagonist to signal regulatory protein alpha (SIRPĪ±) receptor, a
myeloid checkpoint inhibitor administered as single agent, and in combination with BI 754091,
a mAb antagonist to PD-1 receptor, a lymphocyte T checkpoint inhibitor.